Silver Book Fact

Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.

Caro J, Getsios D, Migliaccio-Walle K, Ishak J, et al. Rational Choice of Cholinesterase Inhibitor for the Treatment of Alzheimer s Disease in Canada: A comparative economic analysis. BMC Geriatrics. 2003; 3(6). http://www.biomedcentral.com/1471-2318/3/6

Reference

Title
Rational Choice of Cholinesterase Inhibitor for the Treatment of Alzheimer s Disease in Canada: A comparative economic analysis
Publication
BMC Geriatrics
Publication Date
2003
Authors
Caro J, Getsios D, Migliaccio-Walle K, Ishak J, et al.
Volume & Issue
Volume 3, Issue 6
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Based on rates of admission in 1998, delaying admission of Alzheimer’s patients to nursing homes by 1 month could save as much as $1.12 billion a year.  
  • Delaying the onset of Alzheimer’s by only 5 years could reduce the number of people with Alzheimer’s by almost 50% after 50 years.  
  • Delaying the onset and progression of Alzheimer’s disease would reduce the projected number of people with moderate to severe cases of the disase to 4.4 million instead of 10.3 million…  
  • Stem Cell Therapy Study Shows Improved Motor Function in Parkinson’s
     
  • Use of existing or new drugs/compounds for Alzheimer’s prevention could result in a delay of onset of between 2 and 5 years.